{"id":39250,"date":"2026-07-30T10:32:00","date_gmt":"2026-07-30T14:32:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/boehringer-ingelheim-pharmaceuticals-inc-v-ridhisidhi-pllc\/"},"modified":"2026-06-17T02:15:33","modified_gmt":"2026-06-17T06:15:33","slug":"boehringer-ingelheim-pharmaceuticals-inc-v-ridhisidhi-pllc","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/boehringer-ingelheim-pharmaceuticals-inc-v-ridhisidhi-pllc\/","title":{"rendered":"Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC"},"content":{"rendered":"<h2>Litigation summary and analysis: Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, 1:26-cv-00372<\/h2>\n<p>Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Ridhisidhi PLLC in the District of Delaware in a Hatch-Waxman-style patent case filed under No. 1:26-cv-00372. The docket is new and the available public record in this workspace does not include the asserted patents, claims, ANDA\/BLA details, filing date timeline, or infringement and noninfringement\/invalidity positions. No litigation-specific analysis can be produced without those case merits inputs.<\/p>\n<h3>What is the docket entry status for Boehringer Ingelheim v. Ridhisidhi PLLC (1:26-cv-00372)?<\/h3>\n<p>A complete litigation summary requires at minimum: complaint filing date, patents asserted (numbers and expiration dates), asserted dosage forms\/indications, the FDA application referenced (ANDA number or other), and the presence of any Paragraph IV certifications and counterclaims.<\/p>\n<h3>What patents does Boehringer Ingelheim assert in 1:26-cv-00372?<\/h3>\n<p>Litigation analysis depends on the patent estate being challenged:<\/p>\n<ul>\n<li>patent numbers and titles<\/li>\n<li>whether the theory is composition, method-of-use, formulation, or device\/delivery<\/li>\n<li>claim construction posture (if any orders exist)<\/li>\n<li>infringement allegations keyed to product labels or ANDA specs<\/li>\n<\/ul>\n<p>Those specifics are not present in the provided material.<\/p>\n<h3>What Orange Book and FDA application is\u2026<\/h3>","protected":false},"excerpt":{"rendered":"<p>Litigation summary and analysis: Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, 1:26-cv-00372 Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Ridhisidhi PLLC [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34556,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39250","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39250"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39250\/revisions"}],"predecessor-version":[{"id":39381,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39250\/revisions\/39381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/34556"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}